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Paediatric optic pathway gliomas are low-grade brain tumours characterized by slow progression and invalidating visual loss.
Presently there is no strategy to prevent visual loss in this kind of tumour. This study evaluated the effects of nerve growth factor
administration in protecting visual function in patients with optic pathway glioma-related visual impairment. A prospective
randomized double-blind phase II clinical trial was conducted in 18 optic pathway glioma patients, aged from 2 to 23 years,
with stable disease and severe visual loss. Ten patients were randomly assigned to receive a single 10-day course of 0.5mg murine
nerve growth factor as eye drops, while eight patients received placebo. All patients were evaluated before and after treatment,
testing visual acuity, visual field, visual-evoked potentials, optic coherence tomography, electroretinographic photopic negative
response, and magnetic resonance imaging. Post-treatment evaluations were repeated at 15, 30, 90, and 180 days Brain magnetic
resonance imaging was performed at baseline and at 180 days. Treatment with nerve growth factor led to statistically significant
improvements in objective electrophysiological parameters (electroretinographic photopic negative response amplitude at 180 days
and visual-evoked potentials at 30 days), which were not observed in placebo-treated patients. Furthermore, in patients in whom
visual fields could still be measured, visual field worsening was only observed in placebo-treated cases, while three of four nerve
growth factor-treated subjects showed significant visual field enlargement. This corresponded to improved visually guided behav-
iour, as reported by the patients and/or the caregivers. There was no evidence of side effects related to nerve growth factor
treatment. Nerve growth factor eye drop administration appears a safe, easy and effective strategy for the treatment of visual loss
associated with optic pathway gliomas.
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Introduction
Paediatric optic pathway gliomas (OPG) are usually low-
grade brain tumours with a slow progression (Binning
et al., 2007). Their major cause of morbidity is the pro-
gressive visual loss associated with infiltration and com-
pression of the optic pathways by tumour cells. Retinal
ganglion cells (RGCs) are thought to be a major target of
disease-induced visual damage in OPG (Hegedus et al.,
2009; Kim et al., 2010; Gu et al., 2014). The retinal
nerve fibre layer (RNFL), the most proximal region of the
afferent visual pathway comprised by RGC axons, has been
considered a structural marker of visual integrity in patients
with OPG (Gu et al., 2014). Reduced RNFL thickness due
to RGC axonal loss has actually been associated with clin-
ically evident visual loss in children with OPGs.
At present, no specific therapy is available for OPG-
induced visual impairment (Kalin-Hajdu et al., 2014).
Nerve growth factor (NGF) was the first discovered neuro-
trophin. Originally known for its role in the development
and survival of sympathetic neurons, NGF has proved
effective in promoting neural recovery after inflammatory,
ischaemic, and toxic injuries in a large number of experi-
mental and clinical models (Verge et al., 1992; Chiaretti
et al., 2008).
In the optic pathways, NGF receptors are found in
RGCs, whose axons form the first part of the optic path-
ways (Carmignoto et al., 1991; Caleo et al., 2000), as well
as in the visual cortex (Rossi et al., 2002; Tropea et al.,
2002). In both regions, NGF administration can ameliorate
visual function, as shown by preclinical studies. Intraocular
NGF administration has been shown to delay or prevent
RGC loss and the concomitant visual loss induced by optic
nerve transection and ocular ischaemia in experimental
animal models (Carmignoto et al., 1991; Porciatti and
Ventura, 2012). When directly applied in the visual
cortex, NGF can boost glutamate release and improve
visual responses to impoverished visual inputs (Sala et al.,
1998; Pizzorusso et al., 1999).
Testing the effectiveness of NGF in human visual pathol-
ogies has been hindered by the search for non-invasive ad-
ministration strategies to bypass the blood–retina barrier.
At present NGF administration, in the form of eye drops,
appears a promising way to circumvent this difficulty.
Recent experimental animal studies showed that NGF
applied on the conjunctiva can reach the retina and the
optic pathway (Lambiase et al., 2005), as well as the cere-
bral cortex (Capsoni et al., 2009), exerting biological activ-
ities in these regions. Clinical studies have also shown the
safety and effectiveness of NGF eye drops in patients with
corneal ulcers (Lambiase et al., 2007), as well as in patients
with severe glaucoma (Lambiase et al., 2010).
In a previous pilot open-label, longitudinal study invol-
ving five paediatric patients suffering from severe visual
impairment associated with OPG, no adverse effect was
found on tumour growth, but rather a promising transient
increment in visual-evoked potential (VEP) amplitude in all
treated patients (Falsini et al., 2011). Furthermore, in an
adult patient with a bilateral pre-chiasmatic OPG, a dra-
matic improvement in visual acuity and visual field was
observed following repeated short-term courses of NGF
eye drop treatment (Chiaretti et al., 2011). As promising
as these results have been, the possibility of a placebo effect
and examiner bias was inherent in this kind of open-label
pilot study, as was the risk of other potential sources of
bias, such as improvement due to repeat testing and inter-
session variability.
For these reasons, the present randomized, double-blind,
placebo controlled clinical study was designed to evaluate
the efficacy of NGF eye-drop administration in protecting
visual function in patients with OPG-associated visual loss.
Materials and methods
Eligibility
Patients with OPG-induced visual impairment, with or without
neurofibromatosis type 1 (NF1), admitted to the Division of
Paediatric Oncology at the ‘Agostino Gemelli’ Hospital in
Rome (Italy) were enrolled from September 2012 to
September 2013 (Table 1). A histopathological diagnosis was
not required in the setting of characteristic MRI and clinical
features. Additional eligibility criteria included: age 425 years;
clinically documented visual impairment; no concomitant oph-
thalmological disorders that could affect electrophysiological
assessment; no radiotherapy or chemotherapy within 12
months prior to entry; stable disease at two brain MRI con-
trols, performed at least 6 months apart. The study was con-
ducted in accordance with Good Clinical Practice, the
Declaration of Helsinki and local regulations. Written
informed consent was signed by patients 518 years and by
parents or their legal guardians for patients younger than 18
years. Evidence of assent was obtained from the children. The
protocol was approved by the Ethics Committee of the Sacred
Heart Catholic University in Rome (Italy). This is a registered
clinical trial (EudraCT n. 2011-003030-14).
Study design
A two-arm, placebo-controlled, randomized clinical trial
was performed. Patients were randomly (1:1) assigned, in a
double-blind manner (both clinicians and patients blind to
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the treatment), to receive NGF or placebo, i.e. an identical
solution not containing NGF. A total of 0.5mg NGF diluted
in 2.5ml saline solution was administered to the conjunctiva of
both eyes three times a day, for 10 consecutive days. In each
treatment we administered one drop of the diluted solution per
eye [1 drop = 41.6 ml containing 8.33 mg of NGF (0.05mg of
NGF/daily)]. This amount is considered sufficient to reach and
stimulate NGF receptors, mainly tyrosine receptor kinase A
(TrkA), in most cerebral cholinergic areas of the brain and
optic pathways, as previously reported (Eriksdotter Jo¨nhagen
et al., 1998; Chiaretti et al. 2008). The placebo was adminis-
tered according to the same schedule. At baseline, treated and
placebo cohorts consisted of 10 and eight patients, respect-
ively. After drop-outs for lack of compliance, they comprised
nine and eight patients, respectively.
Safety assessment
Patients were assessed by medical history and physical exam-
ination at baseline, and 15, 30, 90 and 180 days post-
treatment (Supplementary Table 1). The safety analysis was
based on the evaluation of adverse events, symptoms related
to study medication instillation (i.e. burning/stinging/itching,
stickiness, foreign body sensation and blurred vision), ocular
signs at slit lamp examination, and treatment tolerability as
judged by the investigator and patient or parent/guardian. For
preverbal children, unusual discomfort upon instillation was
assessed by parent/guardian. In all patients, if an exacerbated
reaction was noted by the parent/guardian upon instillation of
the study medication to the child, the symptoms of burning/
stinging, stickiness, foreign body sensation and blurred vision
were recorded. Moreover, potential systemic complications
related to NGF administration were monitored, including sys-
temic pain, weight loss, and allergic reactions. MRI (brain
and orbits) were performed at baseline and 180 days after
NGF treatment, using standard imaging parameters and gado-
linium enhancement. Initial and follow-up scans were re-
viewed by a neuroradiologist to evaluate tumour extent and
location, and record any changes after treatment. Progression
of the OPG mass, as reflected by a volumetric increase of
425% from baseline in brain MRI, was regarded as a po-
tential adverse outcome event. Unacceptable toxicity or dis-
ease progression led to discontinuation of the study
medication.
Neuroradiological assessment
Optic gliomas (namely pilocytic astrocytomas) represent a het-
erogeneous group of tumours because their extent and their
magnetic resonance signal intensity are extremely variable.
This kind of tumour may be limited to one or two intra-orbital
optic nerves, may localize mainly to the chiasm, may form a
giant hypothalamic mass, or may involve diffusely all optic
pathways, from the optic nerves to the occipital cortex. The
signal intensity and degree of contrast enhancement of optic
gliomas are heterogeneous, and signal changes may occur
spontaneously, even without any treatment. An expert neuror-
adiologist assessed pre- and post-treatment MRIs of all 18
OPG patients in the study, to recognize changes in size and
signal behaviour in the tumour tissue. Moreover, in patients
examined in our neuroradiological facilities (12/18), we
obtained a more reliable and reproducible measurement of
these tumours, before and after NGF treatment; thus we
decided to select the T2-weighted and post-contrast
T1-weighted axial slices, where the tumour is largest, and mea-
sured the largest diameters and the perpendicular ones. In
tumours limited to one optic nerve, we measured the longest
axis of the involved nerve and the transverse diameter. In tu-
mours centred in the optic chiasm, we measured the perpen-
dicular diameters. In tumours with prevalent hypothalamic
growth, we measured the largest diameters of the bulk mass
and the perpendicular one. The measures were obtained using
both T2 and post-contrast T1-weighted axial slices in order to
avoid over- or under-estimation of the heterogeneous enhan-
cing tumours.
Visual outcome measures
All patients were tested at baseline and at 15, 30, 90 and 180
days post-treatment. Visual function tests included physio-
logical subjective and electrophysiological objective measures.
The former comprised the early treatment diabetic retinopathy
study (ETDRS), visual acuity test, and Goldman visual field
perimetry. The latter included Ganzfeld electroretinograms
and flicker-induced VEPs. In addition, retina monitoring by
optical coherence tomography was performed at each time
point.
The following main outcome variables were considered: (i)
best corrected EDTRS visual acuity (BCVA); (ii) Goldman per-
imeter visual field size (V/4 e isopter); (iii) amplitude and
latency of the electroretinographic photopic negative response
(PhNR)—a valuable tool for monitoring longitudinal change in
RGC function in humans (Abed et al., 2015); (iv) amplitude
and latency of the first and second harmonic components of
the flicker VEP recording—a tool for monitoring visual cortical
function, which has proved reliable in monitoring OPG pro-
gression (Falsini et al., 2008); and (v) the thickness of RNFL
obtained from optical coherence tomography screening, a
measure whose alteration has been shown to correlate with
visual loss in a cross-sectional study of OPG in children
(Avery et al., 2011). All parameters were evaluated in terms
Table 1 Demographic and clinical data of enrolled
patients
Gender
Male (n) 11
Female (n) 7
NF1, n (%) 13 (72.2)
Age at enrolment
Median (years) 11.4
Range (years) 2–23
Time from diagnosis to study entry
Median (years) 7.5
Range (years) 1.7–19.6
Time from last treatment to study entry
Median (years) 4.59
Range (years) 0.3–13.3
Type of treatment
Biopsy, n (%) 8 (44.4)
Chemotherapy, n (%) 14 (77.7)
Radiotherapy, n (%) 1 (5.5)
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of their changes from baseline. Given the very low vision con-
ditions of some patients, visual acuities and visual fields were
expected to be less reliable than electrophysiological evalu-
ations (see below). Consequently, in designing the study,
it was decided that physiological measures of visual func-
tion would be included as secondary outcome measures,
while electrophysiological (VEP and electroretinogram) and
anatomical (optical coherence tomography RNFL) measures
were the main outcomes in the evaluation of potential drug
efficacy.
Sample size considerations and
statistical analysis
Preliminary evaluations suggested that 30 patients aged 525
years, with OPG, would be followed by the clinical centre.
Based on a previous pilot study in five OPG patients (Falsini
et al., 2011), this number was estimated to give a power of
80% at an alpha = 0.05 for detecting an average change dif-
ference between the NGF and placebo of at least 30% in VEP
amplitude. Clinical and electrophysiological data were initially
log-transformed to limit skewness. However, the statistical
analysis produced similar results when using the original
scale. Ordinal variables (i.e. presence of adverse events such
as periocular pain, changes in pupillary responses, changes in
visual field extension) were analysed by non-parametric tests.
In the preliminary analyses, multilevel regression techniques
were applied to take into account the potential correlation
between the eyes of each subject. However, visual measures
between the two eyes of each patient were substantially uncor-
related (data not shown), as one would expect from the asym-
metry of OPG. Thus, each eye measure was considered
independently. Visual acuity, visual field size, PhNR and
VEP amplitude were initially evaluated separately by multilevel
regression models for repeated measures, where group
(NGF-treated versus placebo-treated patients) was the
between-subjects factor and time (i.e. the different recording
sessions including baseline and post-treatment visits) the
within-subjects factor. Analyses were performed using raw
data and changes from baseline. Finally a seemingly unrelated
equation regression (Sureg) model was performed where
changes from baseline at each time of all the six electrophysio-
logical experimental outcomes (i.e. amplitude and latency of
PhNR, VEP first and second harmonic, RNFL, and optical
coherence tomography measures) were included as dependent
variables, and the independent variables were the arm group
and the baseline values of each parameter. This analysis is a
generalization of a linear regression model that consists of
several regression equations, each having its own dependent
variable and potentially different sets of exogenous explana-
tory variables. Each equation is a valid linear regression in its
own right and can be estimated separately, but the error terms
are assumed to be correlated across the equations. In all the
analyses, a P-value5 0.05 was considered statistically
significant.
Results
Baseline clinical and demographic characteristics, tumour
location and tumour size of patients are shown in Table
2. At this time there was no significant difference in age,
gender, tumour location, size, and visual function param-
eters between NGF and placebo-treated patients.
Safety
Both NGF and placebo treatments were well tolerated in all
patients, with no severe ocular adverse events reported.
Ocular adverse events considered by the investigator as
related to the study drug were reported in two patients
(20%) treated with NGF eye drops (Supplementary Table
2). These included periocular burning lasting510min after
drug application. All patients of the NGF group reported
that they had experienced phosphenes, often several times
in one day. These were characterized variously as moving
horizontal and/or vertical lines, circles or semi-circular
shapes, crescent moons, lightning bolts, swirling waves,
and flashes covering the entire visual field. However, all
treatment-related ocular adverse events were mild.
Neither corneal inflammation, nor active inflammation of
the anterior chamber was noted in any patient on slit lamp
examination. Overall, patient/guardian-rated and investiga-
tor-rated tolerability was good. MRI control examinations
performed at baseline and 6 months after the end of treat-
ment did not show any disease progression in either NGF-
or placebo-treated patients (Supplementary Fig. 1). In six
patients, tumour size measurements could not be reliably
performed due to non-homogenous morphology of the le-
sions and/or ill-defined margins (Table 2). Optic coherence
tomography did not show retinal alteration over the study
period.
Efficacy evaluation:
electrophysiological results
Examples of electroretinogram and VEP curves in a NGF
and a placebo-treated patient are shown in Fig. 1 at base-
line and at one time during the treatment. Individual curves
representing the time course of the amplitude variation
from baseline in the PhNR (top) and the VEP first har-
monic (bottom) in individual eyes of NGF- (left) and pla-
cebo- (right) treated patients are shown in Fig. 2. A
considerable degree of variability is evidenced from case
to case, but only placebo-treated patients presented major
worsening, while the greatest improvements from baseline
were observed in NGF-treated patients. This qualitative dif-
ference is particularly evident for the VEPs. These same
data are summarized as means and standard deviations
(SD) in Fig. 3. Multivariate analysis with Sureg regression
including all six electrophysiological experimental outcomes
(amplitude and latency of PhNR, VEP first and second har-
monic performed on eyes with no complete loss of visual
function, RNFL and optical coherence tomography meas-
ures) showed significant effects of the treatment on the
PhNR and the VEP first harmonic amplitude. In particular,
this model showed statistically significant mean differences
between NGF-treated and placebo group of PhNR
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amplitude at 180 days (P5 0.01), and of PhNR latency at
15 days (P5 0.01) and at 180 days (P = 0.02) and of VEP
first harmonic amplitude at 30 days (P50.01). Statistically
significant differences between the two study groups were
not observed in any of the other objective visual outcome
measures (Table 3).
Efficacy evaluation: clinical results
Reliable visual field measures were obtained for 18 eyes,
including 10 NGF- and eight placebo-treated eyes, from six
NGF- and five placebo-treated patients, respectively. As
established in the study design, visual field modifications
were evaluated in double-blind manner by two experts,
acting independently of one another. Visual fields were
scored as improved, stable, or worsened compared to base-
line. Expert scoring was coincident. Their results are shown
in Fig. 4A, where, for the sake of simplicity, only the per-
centage of cases with a visual field modification are
reported. Visual field improvement was more frequent in
the NGF- than in placebo-treated eyes (five versus one eyes,
three versus one patients, respectively). Furthermore, visual
field worsening was only observed among placebo-treated
eyes. Examples of the variation of the visual field limits
observed with two different targets in NGF- and placebo-
treated eyes are shown in Fig. 4B, which illustrates a
significant enlargement compared to baseline in the NGF-
treated case. This enlargement was never observed in
placebo-treated patients. Visual acuity did not show any
significant change over the trial in either NGF- or pla-
cebo-treated eyes.
Efficacy evaluation: subjective
patient/caregiver reports
Patients spent the most part of the study in their familiar
surroundings, but could always get in touch with the senior
oncologist to report observations and difficulties. Four of
the NGF-treated patients/caregivers reported improvement
of visually guided behaviour in the patient (e.g. ability to
walk through doorways without assistance). These included
the three NGF patients with improved visual fields. No
subjective improvement was reported for any placebo-
treated patient.
Discussion
This randomized, double-blind, placebo controlled, clinical
study was designed to evaluate the safety and efficacy of
conjunctively applied NGF in children with OPG-associated
visual impairment. We found that NGF treatment led to
significant improvements in objective electrophysiological
parameters (PhNR amplitude and VEP), which were not
observed in placebo-treated patients. Furthermore, among
patients retaining measurable visual fields (50% of the
cases), visual field restriction was only observed in pla-
cebo-treated cases, while one-third of the NGF-treated
cases showed significant visual field enlargement. This cor-
responded to improved visually guided behaviour, as re-
ported by the patient and/or the caregivers (who, due to
the study design, were blind to the treatment nature). There
was no evidence of adverse effects, or serious ocular or
Figure 1 Examples of electroretinogram and VEP curves recorded from a NGF- and a placebo-treated subjects. Grey lines
represent baseline recording. Black lines represent recordings at the specified times. The electroretinogram PhNR component is the negative
deflexion from baseline indicated by the dotted lines in the traces. d = days.
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Figure 2 Individual time courses of PhNR and VEP first harmonic amplitude variation from baseline in NGF- and placebo-
treated patients. Variations from baseline are represented as absolute values. Each curve represents a single eye. Top: PhNR amplitude; Bottom:
VEP first harmonic.
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Table 3 Adjusted estimates of mean differences between NGF and placebo arm for several optical parameters
obtained from seemingly unrelated equations regression model; adjustment is made for the optical parameters at
baseline
Days since treatment start Estimate 95% CI P-value
PHNR amplitude 15 1.17 (0.99;3.34) 0.29
30 1.57 (0.60;3.73) 0.16
90 2.05 (0.11;4.22) 0.06
180 3.11 (0.79;5.43) 0.01
PHNR latency 15 1.47 (0.56;2.37) _0.01
30 0.55 (0.36;1.45) 0.24
90 0.59 (0.31;1.50) 0.20
180 1.16 (0.19;2.13) 0.02
VEP amplitude I 15 0.18 (2.42;2.78) 0.89
30 3.72 (1.12;6.32) 0.01
90 0.05 (2.55;2.64) 0.97
180 0.20 (2.98;2.58) 0.89
VEP amplitude II 15 0.37 (0.90;0.16) 0.17
30 0.07 (0.46;0.59) 0.80
90 0.23 (0.29;0.76) 0.39
180 0.10 (0.47;0.66) 0.74
RNFL 15 6.48 (16.81;3.85) 0.22
30 1.82 (12.14;8.51) 0.73
90 0.27 (10.06;10.60) 0.96
180 5.40 (16.43;5.63) 0.34
OCT 15 6.34 (18.79;31.49) 0.62
30 21.03 (46.16;4.11) 0.10
90 9.31 (15.83;34.44) 0.47
180 8.15 (18.60;34.91) 0.55
Note: estimated parameters for optical values at baseline are not reported in the table. Values highlighted in bold indicate a statistical significance.
OCT = optical coherence tomography.
Figure 3 Mean amplitude variation in PhNR and VEP first harmonic over time in NGF- and placebo-treated patients. Data are
represented as means and SD.
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systemic safety issues related to NGF treatment. MRI dis-
played stable tumour size.
One first important issue to consider is the lack of
adverse effects of the treatment. NGF eye-drops have
already been tested in a number of clinical eye conditions,
including corneal ulcers and glaucoma. None of the pa-
tients included in such studies experienced significant ad-
verse effects either topically or systemically (Lambiase
et al., 2007, 2010). Similarly, no adverse effect was
observed in OPG patients enrolled in our previous pilot
open-label studies with NGF eye drops (Falsini et al.,
2011). These studies represented our base reference in the
trial design. In line with these studies, no major visual
adverse effect was observed in the present study. A critical
issue in the study design was the risk of adverse effects of
the treatment on tumour progression. A low risk expect-
ation was based on two levels of observation. Low-grade
astrocytomas are characterized by markedly reduced
(75% less) NGF and TrkA expression, and upregulation
of the pro-apoptotic p75 NGF receptor (Chiaretti et al.,
2004). It is postulated that this is related to the slow
growth of these tumours, and to the potential differentiat-
ing role of NGF on tumour cells. In line with this view,
astrocytoma and low grade glioma cells can undergo dif-
ferentiation when exposed to NGF in vitro (Kraft et al.,
2001), and preclinical experiments show inhibition of
glioma cell proliferation following NGF in vivo administra-
tion (Verge et al., 2002). For these reasons we considered it
unlikely that a limited acute dose of NGF administered as
eye drops would interfere with OPG growth. In line with
this view, none of the six patients treated in our previous
pilot studies showed tumour growth either in the 6-month
period of the study (Chiaretti et al., 2011; Falsini et al.,
2011), or in the 2 years that have now elapsed since their
treatment. This expectation has been confirmed in the pre-
sent study where no tumour growth was observed 6
months after the trial short-term NGF treatment, as as-
sessed by expert neuroradiological review of brain MRI
scans taken at baseline and at 6 months from the
trial. The main expectations from the trial was the proof-
of-principle of a non-invasive therapeutic strategy to coun-
teract the visual decline that is a constant and still unmet
feature of OPGs. Our two previous open-labelled studies
had already raised hopes that NGF treatment could provide
such a tool, by showing improved VEP in treated patients.
The present double-blind study provides solid grounds for
such an expectation, showing that, although with consider-
able variability from patient to patient, NGF treatment led
to improved objective and subjective visual parameters,
which are not found in placebo-treated patients. While
the possibility of a placebo effect and examiner bias was
inherent in our previous open-label pilot studies, this can
likely be excluded in the present double-blind design, as
neither the examiner nor the patient or caregivers were
aware of whether the subject was receiving treatment or
placebo. The double-blind design also enables other poten-
tial sources of bias to be excluded, such as improvement
due to repeat testing and intersession variability, as these
would have affected NGF- and placebo-treated patients
alike. Significantly improved objective and subjective
visual outcomes in treated patients, together with the lack
of similar effects in placebo-treated cases, suggests biolo-
gical activity of NGF treatment. NGF receptors are found
on the RGCs—whose axons form the pre-geniculate part of
the optic pathway, as well as in the visual cortex. In animal
models, intra-ocular NGF has proved able to preserve RGC
function following ischaemic or traumatic insults (Verge
et al., 1992; Siliprandi et al., 1993; Lambiase et al.,
2009; Sivilia et al., 2009; Bai et al., 2010). Similarly,
when directly applied in the visual cortex, NGF can
boost excitatory inputs, improve visual responses
(Pizzorusso et al., 1999; Galuske et al., 2000), and promote
visual cortical plasticity (Maffei et al., 1992). In the present
study, we found that a short (10 day) period of treatment
resulted in a long-term (3–6 months) stabilization/improve-
ment of visual function. The period of treatment and the
Figure 4 Visual field variations in NGF- and placebo-
treated patients. (A) Number of improved and worsened visual
fields (VFs) in NGF- and placebo-treated patients at various times
after treatment. The actual numbers of visual fields is reported on
each bar. Visual field assessment was performed qualitatively in
double-blind by two independent observers. (B) Examples of visual
field variations from baseline during the trial in a NGF- and a pla-
cebo-treated subject. Traces are obtained using the III4e (left) and
V4e (right) targets. d = days.
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cumulative dose were chosen on the basis of our previous
pilot studies (Chiaretti et al., 2011; Falsini et al., 2011),
indicating that this treatment regimen was safe, and show-
ing promising functional results, suggesting efficacy. Our
intent was to test the hypothesis that this short treatment
would be able to show a significant effect when compared
to placebo. The long-term effect on visual function is con-
sistent with a prolonged change in visual neurons following
NGF exposure. Different biological activities have been
proposed to explain the mechanisms of action of NGF on
the visual system. In animal models, NGF binding to TrkA
upregulates BCL2 protein levels, which protects RGC from
apoptosis by preventing caspase activation (Coassin et al.,
2008). Following a single NGF administration, the tran-
scriptional activity activated by the NGF pathway induces
a pro-survival change in BAX/BCL2 balance and C-Jun
expression in RGCs, with neuroprotective effects that
may last several months (Sivilia et al., 2009). Based on
these studies, we speculate that neuroprotection of RGCs
by NGF may represent a main mechanism active in eliciting
the reported prolonged effects of NGF in children with
optic gliomas. We cannot exclude, however, that the effects
of NGF may relate not only to a protective activity against
neural apoptosis. NGF is known to act at different levels to
promote neuronal recovery following ischaemic, inflamma-
tory and traumatic injuries: through neosynaptogenetic
mechanism, by promoting axonal regeneration
(Shimohama et al., 1993), by regulating miRNA expression
(Shi, 2015), and by directly affecting induction of other
growth factors, such as BDNF, whose neuroprotective ef-
fects on RGCs has been reported (Chen et al., 2001; Frost,
2001). Moreover, it has also been demonstrated that ocular
administration of NGF could elicit an NGF-mediated neu-
roprotective effect in several brain nuclei (Calza et al.,
2001; Tirassa, 2011), including brain regions and cells
not strictly related to the optic pathway. Thus, an improve-
ment of visual cortex physiology elicited by ocular NGF
treatment cannot be excluded.
Together with tumour progression, visual decline in OPG
is the most important reason that paediatric neuro-
oncologists take into account for introducing more aggres-
sive therapy, including chemotherapy and/or radiotherapy
(Fisher et al., 2013). These treatments can have devastating
effects on some patients, and their efficacy in preserving
visual function is variable (Moreno et al., 2010; Fisher
et al., 2013), particularly in the long term (Shofty et al.,
2011). A potential alternative strategy for dealing with
visual deficits in OPG, as shown here with NGF treatment,
could allow a separate management of visual deficits and
tumour progression, potentially reducing the need or the
frequency of more aggressive treatments in this kind of
tumour.
In conclusion, the significant improvement of electro-
physiological and visual subjective measures in treated
eyes, taken with the absence of significant vision loss in
treated eyes, and the lack of significant improvement in
placebo-treated eyes, is a promising finding that merits
further investigation. As this study included a small
number of patients we cannot exclude that some potential
positive effects of NGF, compared to placebo, have been
missed for some parameters. However, we should take into
account that this study was a phase 2 trial and its main
objective was to identify the possible therapeutic efficacy of
this new treatment. A phase 3 trial with a larger number of
subjects and including more clinical centres should be con-
sidered to confirm these encouraging results. These results
suggest that NGF eye drops could provide a potentially safe
strategy to ameliorate visual function in OPGs. This is the
first report of a non-aggressive strategy with beneficial
effects on visual function in childhood OPG.
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